James J. Peters VAMC

The Bronx, New York 10468

1 studies enrolling now · 14 studies all time

What they study most

Alzheimer Disease, Arterial Stiffness, Autonomic Dysreflexia, Autonomic Integrity, Baroreceptor Integrity, Blood Pressure, Cerebral Blood Flow, Chronic Hepatitis C, Clostridioides Difficile Infection, Cognitive Function, HIV, Hepatitis C

Studies at this site

• Autonomic Effects of Spinal Cord Stimulation in Spinal Cord Injury — Recruiting now
• Blood Pressure, Cerebral Blood Flow and Cognition in Spinal Cord Injury — Completed
• RAAS and Arterial Stiffness in SCI — Completed
• The Effects of Normalizing Blood Pressure on Cerebral Blood Flow in Hypotensive Individuals With Spinal Cord Injury — Completed
• Second-line Treatment of HIV-1 With Ritonavir Boosted Atazanavir or Darunavir With an Optimized NRTI Backbone — Withdrawn before enrolling
• Study of BHV-4157 in Alzheimer's Disease — Completed
• Comparison of Ridinilazole Versus Vancomycin Treatment for Clostridium Difficile Infection — Completed
• CLassification of Axial SpondyloarthritiS Inception Cohort — Completed
• Study to Determine the Effectiveness and Safety of a Three Drug Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Not Previously Treated With Currently Available Medications — Completed
• Safety and Efficacy Study of Daclatasvir (BMS-790052) Plus Pegylated Interferon-Alfa 2a and Ribavirin in Patients Coinfected With Untreated Hepatitis C Virus and HIV Virus — Completed
• UNITY 1: A Study of an Investigational Treatment Regimen of Daclatasvir (DCV) + Asunaprevir (ASV) + BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) for 12 Weeks for the Treatment of Chronic Hepatitis C Virus (HCV) Genotype 1 Infection in Non-cirrhotic Subjects — Completed
• Study of Daclatasvir (BMS-790052) Add-on to Standard of Care in Treatment- naïve Patients — Completed
• Study of the Anti-HCV Drug (BMS-790052) Combined With Peginterferon and Ribavirin in Patients Who Failed Prior Treatment — Completed
• Study of BMS-650032 With Peginterferon Alfa-2a Plus Ribavirin — Completed